Development asset linked to Jieming QU in public FDA and regional records. Molecular target: Hemagglutinin.
- Target
- Hemagglutinin
- Mechanism
- Hemagglutinin negative modulator
pharma · 2019-nCoV
Jieming QU
Jieming QU drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Jieming QU pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Jieming QU drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.